GBIO Stock Price, Generation Bio Co Quote, Chart

Market Summary

USD3.67-0.10

Market Closed

-2.65%

GBIO Stock Price

View Fullscreen

GBIO RSI Chart

GBIO Valuation

Market Cap

244.2M

Price/Earnings (Trailing)

-1.44

Price/Sales (Trailing)

24.51

Price/Free Cashflow

-3.74

GBIO Price/Sales (Trailing)

GBIO Profitability

Return on Equity

-128.05%

Return on Assets

-59.12%

Free Cashflow Yield

-26.75%

GBIO Fundamentals

GBIO Revenue

Revenue (TTM)

10.0M

Rev. Growth (Qtr)

41.04%

GBIO Earnings

Earnings (TTM)

-169.0M

Earnings Growth (Yr)

-132.13%

Earnings Growth (Qtr)

-111.73%

Breaking Down GBIO Revenue

Last 7 days

22.7%

Last 30 days

23.2%

Last 90 days

72.3%

Trailing 12 Months

-12.0%

How does GBIO drawdown profile look like?

GBIO Financial Health

Current Ratio

8.01

GBIO Investor Care

Shares Dilution (1Y)

1.30%

Diluted EPS (TTM)

-2.55

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q4
2024	10.0M	0
2023	0	5.9M
2018	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Generation Bio Co

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 15, 2024	stanton matthew	acquired	-	-	1,674	chief scientific officer
Apr 15, 2024	howze yalonda	sold (taxes)	-14,541	3.7	-3,930	chief legal officer
Apr 15, 2024	stanton matthew	sold (taxes)	-1,820	3.7	-492	chief scientific officer
Apr 15, 2024	samayoa phillip	acquired	-	-	1,147	chief strategy officer
Apr 15, 2024	norkunas matthew	sold (taxes)	-3,640	3.7	-984	chief financial officer
Apr 15, 2024	norkunas matthew	acquired	-	-	3,347	chief financial officer
Apr 15, 2024	samayoa phillip	sold (taxes)	-1,246	3.7	-337	chief strategy officer
Apr 15, 2024	mcdonough geoff	acquired	-	-	5,274	president and ceo
Apr 15, 2024	mcdonough geoff	sold (taxes)	-5,727	3.7	-1,548	president and ceo
Apr 15, 2024	paone antoinette	sold (taxes)	-1,731	3.7	-468	chief operating officer

Which funds bought or sold GBIO recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 17, 2024	Artal Group S.A.	added	0.58	6,877,500	11,520,500	0.29%
May 16, 2024	JANE STREET GROUP, LLC	reduced	-73.44	-60,915	115,681	-%
May 16, 2024	CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	reduced	-38.92	6,232	18,531	-%
May 15, 2024	TWO SIGMA INVESTMENTS, LP	reduced	-0.92	755,418	1,278,600	-%
May 15, 2024	DEUTSCHE BANK AG\	added	1.56	3,060,550	5,093,870	-%
May 15, 2024	BAKER BROS. ADVISORS LP	new	-	1,510,860	1,510,860	0.02%
May 15, 2024	MILLENNIUM MANAGEMENT LLC	reduced	-70.41	-335,465	906,564	-%
May 15, 2024	MARSHALL WACE, LLP	sold off	-100	-203,918	-	-%
May 15, 2024	Yiheng Capital Management, L.P.	new	-	779,527	779,527	0.04%
May 15, 2024	TWO SIGMA ADVISERS, LP	added	57.06	1,007,290	1,357,750	-%

Are Funds Buying or Selling GBIO?

Are funds buying GBIO calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own GBIO

No. of Funds

Unveiling Generation Bio Co's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	price t rowe associates inc /md/	10.5%	6,926,174	SC 13G/A
Feb 13, 2024	bb biotech ag	5.5%	3,608,280	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Feb 09, 2024	atlas venture fund x, l.p.	10.8%	7,111,939	SC 13G/A
Jan 08, 2024	blackrock inc.	4.8%	3,168,415	SC 13G/A
Dec 11, 2023	fmr llc	-	0	SC 13G/A
Mar 24, 2023	modernatx, inc.	8.9%	5,859,375	SC 13G
Feb 14, 2023	t. rowe price investment management, inc.	6.0%	3,577,755	SC 13G
Feb 14, 2023	bb biotech ag	6.1%	3,608,280	SC 13G/A
Feb 14, 2023	price t rowe associates inc /md/	12.2%	7,261,046	SC 13G/A

Recent SEC filings of Generation Bio Co

View All Filings

Date Filed	Form Type	Document
May 13, 2024	10-Q	Quarterly Report
May 13, 2024	8-K	Current Report
Apr 24, 2024	ARS	ARS
Apr 24, 2024	DEF 14A	DEF 14A
Apr 24, 2024	DEFA14A	DEFA14A
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading
Apr 17, 2024	4	Insider Trading

Peers (Alternatives to Generation Bio Co)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	50.9B	6.8B	28.49%	6.05%	-8.53	7.44	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	18.9B	2.0B	2.79%	-21.33%	-56.9	9.43	75.20%	68.82%
BMRN	14.7B	2.5B	-14.30%	-15.94%	71.65	5.96	13.74%	186.89%
INCY	12.8B	3.8B	8.33%	-10.25%	17.2	3.4	8.58%	129.81%
MID-CAP
BBIO	5.6B	107.9M	20.58%	115.45%	-10.31	48.09	54.84%	-28.31%
APLS	5.0B	524.1M	-13.99%	-52.79%	-12.02	9.57	394.93%	39.61%
AXSM	3.6B	251.0M	9.96%	-0.29%	-12.28	14.5	73.58%	-86.73%
ARWR	3.1B	240.7M	9.94%	-31.73%	-6.53	12.77	-1.03%	-213.43%
ACAD	2.4B	813.8M	-14.08%	-36.34%	-1.4K	3	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	3.06%	35.16%	29.91	4.73	60.38%	-34.49%
NVAX	1.8B	996.6M	234.45%	75.34%	-4.58	1.83	-26.66%	65.49%
CRBP	480.9M	881.7K	21.10%	351.81%	-14.25	481.06	-77.61%	33.36%
INO	310.9M	4.9M	8.40%	53.85%	-2.49	63.89	-54.97%	48.23%
IBIO	17.1M	2.1M	4.76%	108.64%	-0.74	7.61	-13.45%	69.54%

Generation Bio Co News

Latest updates

Generation Bio Co Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)						(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2018Q4
Revenue	41.0%	4,059	2,878	2,146	880	-	-
Operating Expenses	97.8%	81,693	41,299	33,503	34,799	34,866	-
S&GA Expenses	-100.0%	-	13,376	11,641	12,967	12,866	-
R&D Expenses	-48.7%	14,335	27,923	21,862	21,832	22,000	-
Net Income	-111.7%	-74,500	-35,186	-28,266	-31,066	-32,094	-
Net Income Margin	20.9%	-16.96*	-21.45*	-	-	-	-
Free Cashflow	-13.7%	-33,615	-29,558	-25,506	23,354	-28,432	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																			(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2018Q4
Assets	-23.7%	286	375	381	405	431	376	403	419	444	477	464	491	514	294	311	331	187	42.00	84.00
Current Assets	-16.8%	227	273	298	321	345	287	311	321	342	379	403	433	456	268	286	306	-	18.00	77.00
Cash Equivalents	-40.0%	40.00	66.00	93.00	145	96.00	93.00	140	164	343	381	394	394	368	65.00	61.00	174	107	17.00	9.00
Net PPE	-28.0%	19.00	26.00	22.00	22.00	22.00	22.00	23.00	25.00	28.00	26.00	23.00	24.00	23.00	24.00	23.00	23.00	-	22.00	4.00
Liabilities	-10.3%	154	172	150	151	152	94.00	94.00	94.00	91.00	95.00	57.00	57.00	55.00	26.00	24.00	27.00	26.00	25.00	10.00
Current Liabilities	-29.1%	28.00	40.00	33.00	26.00	23.00	19.00	17.00	16.00	15.00	19.00	15.00	14.00	11.00	11.00	9.00	12.00	-	9.00	7.00
Shareholder's Equity	-35.0%	132	203	232	254	279	282	309	325	353	382	407	433	459	268	287	304	-	-	-
Retained Earnings	-13.0%	-645	-571	-536	-507	-476	-444	-412	-381	-343	-308	-277	-245	-214	-188	-164	-143	-	-108	-47.13
Additional Paid-In Capital	0.5%	778	774	768	762	756	727	721	706	696	690	684	679	673	457	451	448	-	10.00	6.00
Shares Outstanding	0.4%	66.00	66.00	66.00	66.00	66.00	60.00	58.00	57.00	57.00	56.00	56.00	56.00	-	-	-	-	-	-	-
Float	-	-	-	-	299	-	-	-	306	-	-	-	1.00	-	-	-	646	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2018Q4
Cashflow From Operations	-26.9%	-31,697	-24,978	-24,896	24,806	-27,677	-23,003	-20,477	-23,533	-35,435	-20,802	-22,555	-25,437	-23,027	-18,365	-18,513	-15,484	-17,780	-11,807	-11,783	-	-
Share Based Compensation	-33.9%	4,000	6,048	6,004	6,023	6,266	5,847	5,848	6,691	6,066	4,735	4,970	4,970	3,479	3,379	2,161	1,368	1,504	1,085	1,080	1,049	-
Cashflow From Investing	71.1%	-553	-1,914	-26,583	24,415	-5,616	-18,396	-12,614	-158,721	-2,784	7,165	22,165	50,232	113,485	20,351	-93,925	-129,611	-2,011	4,922	3,375	-	-
Cashflow From Financing	-262.3%	-125	77.00	-131	99.00	35,772	83.00	9,313	3,541	52.00	435	306	973	212,957	2,297	-648	212,313	109,133	69.00	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

GBIO Income Statement

2024-03-31

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenues:
Collaboration revenue	$ 4,059	$ 0
Operating expenses:
Research and development	14,335	22,000
General and administrative	10,428	12,866
Loss on lease termination	56,930	0
Total operating expenses	81,693	34,866
Loss from operations	(77,634)	(34,866)
Other income:
Other income and interest income, net	3,093	2,772
Net loss	$ (74,541)	$ (32,094)
Net loss per share, basic (in dollars per share)	$ (1.12)	$ (0.53)
Net loss per share, diluted (in dollars per share)	$ (1.12)	$ (0.53)
Weighted average common shares outstanding, basic (in shares)	66,433,640	60,230,077
Weighted average common shares outstanding, diluted (in shares)	66,433,640	60,230,077
Comprehensive loss:
Net loss	$ (74,541)	$ (32,094)
Other comprehensive income (loss):
Unrealized (losses) gains on marketable securities	(471)	117
Comprehensive loss	$ (75,012)	$ (31,977)

GBIO Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 35,526	$ 66,446
Marketable securities	183,777	197,918
Tenant receivable	0	3,960
Prepaid expenses and other current assets	5,364	4,294
Restricted cash	2,184	0
Total current assets	226,851	272,618
Marketable securities, net of current portion	14,634	0
Property and equipment, net	18,586	25,799
Operating lease right-of-use assets	22,970	69,852
Restricted cash, net of current portion	2,152	5,791
Deferred offering costs	433	433
Other long-term assets	253	265
Total assets	285,879	374,758
Current liabilities:
Accounts payable	1,482	2,346
Accrued expenses and other current liabilities	5,659	16,529
Deferred revenue	12,802	12,919
Operating lease liability	8,368	8,120
Total current liabilities	28,311	39,914
Deferred revenue, net of current portion	38,000	41,942
Operating lease liability, net of current portion	87,577	89,774
Total liabilities	153,888	171,630
Commitments and contingencies (Note 10)
Stockholders' equity:
Preferred stock, $0.0001 par value; 5,000,000 shares authorized and no shares issued or outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, $0.0001 par value; 150,000,000 shares authorized at March 31, 2024 and December 31, 2023; 66,479,100 and 66,205,550 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively	7	7
Additional paid-in capital	778,099	774,224
Accumulated other comprehensive (loss) income	(197)	274
Accumulated deficit	(645,918)	(571,377)
Total stockholders' equity	131,991	203,128
Total liabilities and stockholders' equity	$ 285,879	$ 374,758

About Generation Bio Co

Generation Bio Co., a genetic medicines company, develops therapies for the treatment of rare and prevalent diseases. The company provides a portfolio of programs, including programs for rare and prevalent diseases of the liver and retina. It also focuses on the diseases of skeletal muscle, central nervous system, and oncology. The company was formerly known as Torus Therapeutics, Inc. and changed its name to Generation Bio Co. in November 2017. Generation Bio Co. was incorporated in 2016 and is headquartered in Cambridge, Massachusetts.

CEO	Dr. Cameron Geoffrey McDonough M.D.
WEBSITE	https://generationbio.com
INDUSTRY	Biotechnology
EMPLOYEES	150

Generation Bio Co Frequently Asked Questions

What is the ticker symbol for Generation Bio Co? What does GBIO stand for in stocks?

GBIO is the stock ticker symbol of Generation Bio Co. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Generation Bio Co (GBIO)?

As of Fri May 17 2024, market cap of Generation Bio Co is 244.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of GBIO stock?

You can check GBIO's fair value in chart for subscribers.

What is the fair value of GBIO stock?

You can check GBIO's fair value in chart for subscribers. The fair value of Generation Bio Co is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Generation Bio Co is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for GBIO so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Generation Bio Co a good stock to buy?

The fair value guage provides a quick view whether GBIO is over valued or under valued. Whether Generation Bio Co is cheap or expensive depends on the assumptions which impact Generation Bio Co's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for GBIO.

What is Generation Bio Co's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri May 17 2024, GBIO's PE ratio (Price to Earnings) is -1.44 and Price to Sales (PS) ratio is 24.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. GBIO PE ratio will change depending on the future growth rate expectations of investors.